Literature DB >> 19687320

Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells.

Hans-Peter Horny1.   

Abstract

Mastocytosis, an unusual disorder of bone marrow-derived, clonally transformed hematopoietic progenitor cells, exhibits a broad spectrum of clinical and morphologic features ranging from a self-limiting benign disorder (ie, juvenile cutaneous mastocytosis) to highly aggressive neoplasms like mast cell leukemia. Principally, mastocytosis should be divided in 2 main subentities: cutaneous mastocytosis and systemic mastocytosis mainly involving the bone marrow. Mastocytosis is a morphologic diagnosis and should not be diagnosed on the basis of clinical findings alone. Pathologists need to be aware of the disease and its mimickers. Application of the defined diagnostic criteria can confirm or exclude mastocytosis in most cases. Use of antibodies against tryptase, CD117 (KIT), and CD25 is recommended in every suspected case. Because most cases of systemic mastocytosis show a very low degree of infiltration of the bone marrow, antitryptase and anti-CD117 are of major importance for screening and quantification of mast cells, in particular to detect even small compact infiltrates as the only major diagnostic criterion for mastocytosis. Expression of CD25 on mast cells is defined as a minor diagnostic criterion and is usually seen only in mastocytosis but not in reactive states of mast cell hyperplasia.

Entities:  

Mesh:

Year:  2009        PMID: 19687320     DOI: 10.1309/AJCPPXHMN5CJOXHZ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Authors:  Sheela Shrestha; Barry Wershil; John F Sarwark; Timothy B Niewold; Teresa Philipp; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2010-09

2.  Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.

Authors:  Shouying Du; Hooman H Rashidi; Dzung T Le; Thomas J Kipps; H Elizabeth Broome; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2010-04-23

3.  Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis.

Authors:  Dmitri Atiakshin; Igor Buchwalow; Peter Horny; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2021-01-25       Impact factor: 4.304

4.  CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion.

Authors:  Elena P Moiseeva; Mark L Leyland; Peter Bradding
Journal:  Cell Mol Life Sci       Date:  2012-03-22       Impact factor: 9.261

Review 5.  Advances in anti-IgE therapy.

Authors:  Arzu Didem Yalcin
Journal:  Biomed Res Int       Date:  2015-05-05       Impact factor: 3.411

Review 6.  An overview of the effects of anti-IgE therapies.

Authors:  Arzu Didem Yalcin
Journal:  Med Sci Monit       Date:  2014-09-22

7.  A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.

Authors:  Siham Bibi; Yanyan Zhang; Caroline Hugonin; Mallorie Depond Mangean; Liang He; Ghaith Wedeh; Jean-Marie Launay; Sjoerd Van Rijn; Thomas Würdinger; Fawzia Louache; Michel Arock
Journal:  Oncotarget       Date:  2016-12-13

8.  Mastocytosis in children and adults: clinical disease heterogeneity.

Authors:  Magdalena Lange; Bogusław Nedoszytko; Aleksandra Górska; Anton Zawrocki; Michał Sobjanek; Dariusz Kozlowski
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

Review 9.  Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.

Authors:  Srdan Verstovsek
Journal:  Eur J Haematol       Date:  2013-02       Impact factor: 2.997

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.